SCHEMBL635

SCHEMBL635

Cc1ccc(-c2ccccc2-c2nnnn2C(c2ccccc2)(c2ccccc2)c2ccccc2)cc1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AGTR1 P30556 1/20 0.51
AGTR2 P50052 1/20 0.51
AGT P01019 2/20 0.42
ALDH1A1 P00352 4/20 0.38
TSHR P16473 2/20 0.38
SMN1; SMN2 Q16637 4/20 0.37
NPC1 O15118 4/20 0.37
RAB9A P51151 4/20 0.37
POLB P06746 3/20 0.37
MAPT P10636 2/20 0.37
LMNA P02545 1/20 0.37
TP53 P04637 1/20 0.37
PKM P14618 1/20 0.37
MEN1 O00255 1/20 0.36
KMT2A Q03164 1/20 0.36
L3MBTL1 Q9Y468 1/20 0.36
HPGD P15428 2/20 0.36
NFKB1 P19838 1/20 0.36
NFKB2 Q00653 1/20 0.36
RELA Q04206 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30956037 1.00 AGTR1 (0.51) AGTR1AGTR2AGTALDH1A1TSHR
SCHEMBL8698703 0.91 AGTR1 (0.47) AGTR1AGTR2AGTALDH1A1TSHR
SCHEMBL9235857 0.89 MEN1 (0.42) AGTR1AGTR2ALDH1A1TSHRSMN1; SMN2
SCHEMBL9025603 0.88 MEN1 (0.41) AGTR1AGTR2ALDH1A1TSHRSMN1; SMN2
SCHEMBL7392888 0.88 AGTR1 (0.43) AGTR1AGTR2AGTALDH1A1TSHR
SCHEMBL2053236 0.87 AGTR1 (0.44) AGTR1AGTR2AGTALDH1A1TSHR
SCHEMBL6532773 0.87 AGTR1 (0.46) AGTR1AGTR2AGTALDH1A1TSHR
SCHEMBL31214399 0.87 AGTR1 (0.42) AGTR1AGTR2AGTALDH1A1TSHR
SCHEMBL9262004 0.86 AGTR1 (0.46) AGTR1AGTR2AGTALDH1A1TSHR
SCHEMBL13146764 0.86 AGTR1 (0.55) AGTR1AGTR2AGTTSHRMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 146 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-118108679-A Preparation method of N- (triphenylmethyl) -5- (4' -methylbiphenyl-2-yl) tetrazole 南京法恩化学有限公司 2024-05-31 CN claimed
CN-107935957-B Method for synthesizing high-purity sartan side chain TTBB 江苏仁明生物科技有限公司 2020-08-21 CN claimed
EP-3981753-B1 PREPARATION METHOD FOR TRIPHENYLCHLOROMETHANE LINHAI HUANAN CHEMICAL CO LTD (CN) 2026-04-22 EP disclosed
US-12091375-B2 Preparation method for triphenylchloromethane LINHAI HUANAN CHEMICAL CO., LTD. (CN) 2024-09-17 US disclosed
CN-113748099-B Preparation method of triphenylchloromethane 临海市华南化工有限公司 2024-07-05 CN disclosed
CN-118108679-A Preparation method of N- (triphenylmethyl) -5- (4' -methylbiphenyl-2-yl) tetrazole 南京法恩化学有限公司 2024-05-31 CN disclosed
CN-118108679-A Preparation method of N- (triphenylmethyl) -5- (4' -methylbiphenyl-2-yl) tetrazole 南京法恩化学有限公司 2024-05-31 CN disclosed
CN-118108679-A Preparation method of N- (triphenylmethyl) -5- (4' -methylbiphenyl-2-yl) tetrazole 南京法恩化学有限公司 2024-05-31 CN disclosed
US-20220234970-A1 Preparation Method for Triphenylchloromethane ZHEJIANG HUAHAI PHARMACEUTICAL CO., LTD (CN) 2022-07-28 US disclosed
EP-3981753-A1 PREPARATION METHOD FOR TRIPHENYLCHLOROMETHANE Linhai Huanan Chemical Co., Ltd. (CN) 2022-04-13 EP disclosed
CN-113748099-A Preparation method of triphenylchloromethane 临海市华南化工有限公司 2021-12-03 CN disclosed
WO-1991000277-A1 SUBSTITUTED IMIDAZOLES E.I. DU PONT DE NEMOURS AND COMPANY (US) 1991-01-10 WO disclosed
WO-1991000281-A2 FUSED-RING ARYL SUBSTITUTED IMIDAZOLES E.I. DU PONT DE NEMOURS AND COMPANY (US) 1991-01-10 WO disclosed
EP-0401030-A2 Angiotensin II antagonists MERCK & CO. INC. (US) 1990-12-05 EP disclosed
US-4874867-A Tetrazole intermediates to antihypertensive compounds E. I. DU PONT DE NEMOURS AND COMPANY (US) 1989-10-17 US disclosed
US-4870186-A Tetrazole intermediates to antihypertensive compounds E. I. DU PONT DE NEMOURS AND COMPANY (US) 1989-09-26 US disclosed
EP-0324377-A2 Angiotensin II receptor blocking imidazoles and combinations thereof with diuretics and NSaids E.I. DU PONT DE NEMOURS AND COMPANY (US) 1989-07-19 EP disclosed
WO-1989006233-A1 ANGIOTENSIN II RECEPTOR BLOCKING IMIDAZOLES AND COMBINATIONS THEREOF WITH DIURETICS AND NSAIDS E.I. DU PONT DE NEMOURS AND COMPANY (US) 1989-07-13 WO disclosed
US-4820843-A Tetrazole intermediates to antihypertensive compounds E. I. DU PONT DE NEMOURS AND COMPANY (US) 1989-04-11 US disclosed
EP-0291969-A2 Tetrazole intermediates to antihypertensive compounds E.I. DU PONT DE NEMOURS AND COMPANY (US) 1988-11-23 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220234970-A1 Preparation Method for Triphenylchloromethane TERT, TST, TLL2 AGTR1 4564/4885AGTR2 4281/4885AGT 855/4885
US-12091375-B2 Preparation method for triphenylchloromethane TERT, TST, TLL2 AGTR1 4564/4885AGTR2 4281/4885AGT 855/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.